Major Depressive Disorder News and Research

RSS

Major Depressive Disorder (MDD) is a psychiatric condition characterized by depressed mood or anhedonia (significant loss of interest or pleasure). The condition affects more than 15.7 million adults and approximately 3 million adolescents (aged 13 to 17 years) in the USA each year.

Sharing Miracles: A TV program that features inspirational stories of real patients

Major League Baseball slugger Aaron Boone will be featured on January's episode of Sharing Miracles - a 30-minute public affairs television program that tells the compelling and inspirational stories of real patients. Sharing Miracles airs every week on more than 300 television stations nationwide.

31 Dec 2009

Naurex commences dosing in its GLYX-13 Phase I clinical trial for treatment-resistant depression

Naurex Inc., a new clinical stage company developing innovative treatments for depression and other CNS disorders based on its novel GFPA NMDA receptor modulators, today announced that it has initiated a Phase I clinical trial of its lead compound GLYX-13 and has successfully dosed the first subjects in the study.

16 Dec 2009

Depression drug TC-5214 earns USF its most lucrative patent royalties to date

A depression drug created and patented by a team of University of South Florida researchers is at the center of major deal between global pharmaceutical company AstraZeneca PLC and Targacept, Inc., earning the university its potentially most lucrative patent royalties to date.

9 Dec 2009

Most antidepressant medications raise serotonin levels and miss key target of clinical depression

A key brain protein called monoamine oxidase A (MAO-A) - is highly elevated during clinical depression yet is unaffected by treatment with commonly used antidepressants, according to an important study published today in the Archives of General Psychiatry. The study has important implications for our understanding of why antidepressants don't always work.

9 Dec 2009

Mylan Pharmaceuticals signs settlement and license agreements with Wyeth

Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. has entered into settlement and license agreements with Wyeth, now part of Pfizer, relating to Venlafaxine Hydrochloride (HCl) Extended Release (ER) Capsules, 37.5 mg, 75 mg and 150 mg, the generic version of Wyeth's Effexor XR® Capsules, a treatment for major depressive disorder.

9 Dec 2009

Young adults with higher blood lead levels more likely to have panic disorders, reveals research

Young adults with higher blood lead levels appear more likely to have major depression and panic disorders, even if they have exposure to lead levels generally considered safe, according to a report in the December issue of Archives of General Psychiatry, one of the JAMA/Archives journals.

8 Dec 2009

Individuals taking antidepressants may experience personality change, says new report

Individuals taking a medication to treat depression may experience changes in their personality separate from the alleviation of depressive symptoms, according to a report in the December issue of Archives of General Psychiatry, one of the JAMA/Archives journals.

8 Dec 2009

FDA approves once-daily SEROQUEL XR Extended Release Tablets

AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved once-daily SEROQUEL XR® (quetiapine fumarate) Extended Release Tablets as adjunctive (add-on) treatment to antidepressants in adults with Major Depressive Disorder (MDD).

4 Dec 2009

AstraZeneca and Targacept enter into agreement to develop and commercialize TC-5214

AstraZeneca and Targacept, Inc. today announced a collaboration and license agreement for the global development and commercialization of TC-5214, Targacept’s late-stage investigational product for major depressive disorder (MDD).

3 Dec 2009

New PBS documentary examines why people view happiness as an elusive goal

On the eve of a new year, as millions of Americans struggle to find more meaning in their lives, Vulcan Productions and NOVA/WGBH have teamed up with Harvard psychologist and best-selling author of Stumbling on Happiness, Professor Daniel Gilbert, to produce This Emotional Life. This three-part documentary premieres on PBS January 4-6, 2010 (at 9:00 p.m. check local listings) and examines why people find happiness to be such an elusive goal.

2 Dec 2009

Eli Lilly's Cymbalta receives FDA approval

The U.S. Food and Drug Administration (FDA) has approved Cymbalta® (duloxetine HCl) for the maintenance treatment of generalized anxiety disorder (GAD) in adults, announced Eli Lilly and Company (NYSE: LLY).

30 Nov 2009

Potential benefits of Labopharm's novel trazodone formulation published

Labopharm Inc. today announced an article has been published in the international journal of neuropsychiatric medicine, CNS Spectrums October, 2009 issue, citing the potential benefit of its novel trazodone formulation, which contains Contramid(R). Labopharm's Contramid is the clinically validated proprietary technology that controls the release of active substances from oral medications to optimize drug delivery.

11 Nov 2009

$Connection between depression and loss of bone mass leads to osteoporosis and fractures$

Connection between depression and loss of bone mass leads to osteoporosis and fractures

Research carried out among thousands of people has shown a clear connection between depression and a loss of bone mass, leading to osteoporosis and fractures.

9 Nov 2009

Rush University Medical Center opens TMS Clinic to offer non-drug treatment for depression

Rush University Medical Center has opened the Transcranial Magnetic Stimulation (TMS) Clinic to offer patients suffering from major depression a safe, effective, non-drug treatment. TMS therapy is the first FDA-approved, non-invasive antidepressant device-based treatment clinically proven for treatment of depression.

6 Nov 2009

Positive top-line results from Phase IIb clinical trial of cariprazine announced

Forest Laboratories, Inc. and Gedeon Richter Plc today announced positive top-line results from a Phase IIb clinical trial of the novel, investigational antipsychotic agent cariprazine for the treatment of acute exacerbation of schizophrenia.

29 Oct 2009

CNS Response to present results from depression efficacy study at U.S. Psychiatric and Mental Health Congress

CNS Response, Inc. announced that the company will present top-line results from its multi-site clinical trial next week at the U.S. Psychiatric and Mental Health Congress. "Referenced-EEG (rEEG®) Efficacy Compared to Star*D for Patients with Depression Treatment Failure: First Look at Final Results," will be presented by Charles DeBattista, M.D. on Monday, November 2nd, at 3:45 to 6:45 p.m. The conference is being held at the Mandalay Bay South Convention Center in Las Vegas, NV.

29 Oct 2009

New clinical uses for old hypertension drug leads to several patents

University of South Florida neuroscientist R. Douglas Shytle's discovery of successful new clinical uses for mecamylamine, a drug once used to treat hypertension, has led to several issued patents on mecamylamine and related compounds. Earlier this month, Shytle, associate professor and research scientist at the USF Center of Excellence for Aging and Brain Repair and the USF Silver Child Development Center, received the university's 2009 "Excellence in Innovation" award.

28 Oct 2009

Major Depressive Disorder News and Research

Further Reading

Sharing Miracles: A TV program that features inspirational stories of real patients

Naurex commences dosing in its GLYX-13 Phase I clinical trial for treatment-resistant depression

Depression drug TC-5214 earns USF its most lucrative patent royalties to date

Most antidepressant medications raise serotonin levels and miss key target of clinical depression

Mylan Pharmaceuticals signs settlement and license agreements with Wyeth

Young adults with higher blood lead levels more likely to have panic disorders, reveals research

Individuals taking antidepressants may experience personality change, says new report

FDA approves once-daily SEROQUEL XR Extended Release Tablets

AstraZeneca and Targacept enter into agreement to develop and commercialize TC-5214

New PBS documentary examines why people view happiness as an elusive goal

Eli Lilly's Cymbalta receives FDA approval

Potential benefits of Labopharm's novel trazodone formulation published

Connection between depression and loss of bone mass leads to osteoporosis and fractures

Rush University Medical Center opens TMS Clinic to offer non-drug treatment for depression

Positive top-line results from Phase IIb clinical trial of cariprazine announced

CNS Response to present results from depression efficacy study at U.S. Psychiatric and Mental Health Congress

New clinical uses for old hypertension drug leads to several patents

New therapy for decreasing anxiety and improving psychological well-being in children

Study explores the link between child sexual abuse and inability to express emotions in adulthood

Schering-Plough announces 2009 third quarter financial results

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

How microplastics and bacteria interact to drive antibiotic resistance

Latest News